Lisa Miller

Articles

Expert Sheds Light on Identifying "Lynch-Like Syndrome" in Patients With dMMR Rectal Cancer

October 12th 2016

To properly manage patients with DNA mismatch repair deficiency rectal cancer, one must have a well-rounded understanding of the molecular and clinical causes and risks associated with this subgroup of patients.

5 Key Areas in Emerging Immunotherapy Research Stand Out

September 24th 2016

Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors

Leptomeningeal Metastases More Common in EGFR-Mutant NSCLC

August 22nd 2016

In patients with EGFR-mutant non–small cell lung cancer, the incidence of leptomeningeal metastases is found to be common; moreover, the optimal treatment for this occurrence was determined to be tyrosine kinase inhibitors.

Low Recurrence Score in Breast Cancer Shows No Survival Benefit With Chemo Plus Hormonal Therapy

July 28th 2016

Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.

Dual HER2-Targeted Approach Delivers Greatest Neoadjuvant Benefit in HER2+ Breast Cancer

July 28th 2016

In terms of neoadjuvant therapies for patients with HER2-positive breast cancer, dual anti–HER2-directed agents seem to have the most benefit.

Possible Biomarker Could Determine Risk of Colon Cancer Recurrence

July 15th 2016

A liquid biopsy test of circulating tumor DNA for residual disease may be able to determine the risk of recurrence for patients with stage II colon cancer beyond radiologic tests and clinicopathological risk features.

Abemaciclib Active Against Multiple Tumor Types

May 30th 2016

Phase I trial results demonstrate that abemaciclib, a CDK 4/6 inhibitor, had significant clinical activity and an overall response rate of 31% in patients with hormone receptor-positive breast cancer.

Study Calls for Basing Lung Cancer Screening Guidelines on Individual Risk

May 26th 2016

An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy, while saving more lives than the current US Preventive Services Task Force guidelines for lung cancer screening.

IHC Staining Found Effective for ROS1+ NSCLC

May 22nd 2016

The use of immunohistochemistry could be a more cost- and time-efficient first-line screening method for identifying ROS1 gene rearrangements to predict eligibility for crizotinib (Xalkori) for patients with non–small cell lung cancer compared with fluorescence in-situ hybridization.